ROCKWELL MEDICAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | |||||||||||||
Three MonthsEndedSeptember 30, 2018 | Three MonthsEndedSeptember 30, 2017 | Nine Months EndedSeptember 30, 2018 | Nine Months EndedSeptember 30, 2017 | ||||||||||
Sales | $ | 16,672,416 | $ | 14,626,904 | $ | 46,534,358 | $ | 42,462,265 | |||||
Cost of Sales | 14,703,606 | 13,555,853 | 49,303,048 | 37,535,454 | |||||||||
Gross Profit (Loss) | 1,968,810 | 1,071,051 | (2,768,690) | 4,926,811 | |||||||||
Selling, General and Administrative | 6,159,141 | 4,791,636 | 15,182,048 | 17,433,530 | |||||||||
Settlement Expense, net of Reimbursement | — | — | 1,030,000 | — | |||||||||
Research and Product Development | 808,192 | 1,304,658 | 4,033,494 | 4,195,003 | |||||||||
Operating Loss | (4,998,523) | (5,025,243) | (23,014,232) | (16,701,722) | |||||||||
Interest and Investment Income (Loss) | 28,891 | (31,751) | 264,287 | (180,279) | |||||||||
Net Loss | $ | (4,969,632) | $ | (5,056,994) | $ | (22,749,945) | $ | (16,882,001) | |||||
Basic and Diluted Net Loss per Share | $ | (0.10) | $ | (0.10) | $ | (0.44) | $ | (0.33) | |||||
Basic and Diluted Weighted Average Shares Outstanding | 51,288,537 | 51,260,975 | 51,288,462 | 50,995,079 | |||||||||
